Home > > > Mycoplasma Diagnostics Market to Reach USD 2.1 Bn by 2034, Growing at 7.4% CAGR

Mycoplasma Diagnostics Market to Reach USD 2.1 Bn by 2034, Growing at 7.4% CAGR

Author : kaustubh Ravan | Published On : 10 Mar 2026

The global mycoplasma diagnostics market was valued at USD 1.0 Bn in 2023 and is expected to experience notable growth during the forecast period. The market is estimated to expand at a CAGR of 7.4% from 2024 to 2034, driven by the increasing prevalence of mycoplasma infections, rising demand for rapid and accurate diagnostic testing, and growing adoption of advanced molecular diagnostic technologies. With expanding research activities and improved laboratory testing capabilities, the market is projected to reach USD 2.1 Bn by the end of 2034.

Mycoplasma is a bacterium (or germ) that can infect different parts of the human body. Mycoplasma diagnostics is a class of medical tests or examinations conducted to evaluate nucleic acids or proteins at a molecular level. This aids in the early detection of mycoplasma contaminations in samples.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1677

Key Findings of the Market Report

  • Kits & Reagents is the dominant product segment (~55.7%–57.8% share), creating recurring revenue as labs shift away from home-brew assays to standardized, validated commercial kits.
  • PCR/NAT Technology holds the largest technology share (~47%–63.8%), favored for its ability to provide results in hours rather than the weeks required for microbial culture.
  • Cell Line Testing is the primary application (~41% share), as mycoplasma remains the most common and difficult-to-detect contaminant in laboratory cell cultures.
  • Pharmaceutical & Biotechnology Companies are the leading end-users (~35%–64% share), increasingly outsourcing testing to Contract Development and Manufacturing Organizations (CDMOs).
  • North America leads the global market (~35%–49% share), while Asia-Pacific is the fastest-growing region (~11%–18% CAGR) due to the expansion of biosimilar production in India and China.

Global Mycoplasma Diagnostics: Growth Drivers in 2026

  • The Cell & Gene Therapy (CGT) Boom: 2026 marks a peak in CGT manufacturing. Because these therapies use living cells that cannot be heat-sterilized, rapid mycoplasma testing is a regulatory "must-have" before patient administration.
  • Respiratory Infection Resurgence: A global increase in Mycoplasma pneumoniae (walking pneumonia) cases has transitioned the clinical side of the market from specialized research to mainstream hospital diagnostics.
  • Transition to Digital PCR (dPCR): In 2026, labs are moving toward dPCR for absolute quantification of mycoplasma DNA, providing even higher sensitivity than standard qPCR for "zero-tolerance" biomanufacturing environments.
  • Regulatory Stringency: Updated FDA and EMA mandates for biologics and vaccine testing are forcing manufacturers to adopt more comprehensive biological safety protocols, directly boosting the testing services market.

Key Players & Recent Developments

The market is characterized by a mix of life science "Big Tech" and specialized biosafety labs.

  • Thermo Fisher Scientific Inc. (Market leader with ~24.3% share in the pneumonia kit segment).
  • bioMérieux SA (Leader in rapid automated testing with the BIOFIRE MYCOPLASMA platform).
  • Merck KGaA (Provides a wide range of reagents and Millipore-branded testing solutions).
  • Lonza Group (Strong presence in cell culture-specific detection).
  • Charles River Laboratories (Leading the service-based/outsourced testing segment).
  • Sartorius AG
  • InvivoGen (Specializes in rapid detection and elimination kits).

Recent Milestones (2025–2026)

  • February 2026: The Business Research Company reported that the market reached USD 1.38 billion this year, citing a 12.1% CAGR driven by rapid molecular diagnostic adoption.
  • January 2026: bioMérieux reported steady growth in diagnostic revenues, emphasizing the success of automated workflows that reduce human error in sample preparation.
  • Late 2025: QIAGEN expanded its QIAcuity line with new kits specifically designed for mycoplasma detection in cell and gene therapy manufacturing.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=1677&ltype=S

Global Mycoplasma Diagnostics: Segmentation

By Product & Service

  • Kits & Reagents (Assays, Stains, Elimination Kits) — (Market Leader)
  • Instruments (PCR Machines, Automated Counters)
  • Services (Outsourced Lab Testing)

By Technology

  • PCR (qPCR, Digital PCR) — (Dominant Technology)
  • ELISA / Immunoassays
  • Microbial Culture (Gold Standard/Traditional)
  • DNA Staining

By End-User

  • Pharmaceutical & Biotechnology Companies (Largest Share)
  • Contract Research Organizations (CROs/CDMOs) — (Fastest Growth)
  • Academic Research Institutes & Cell Banks

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: [email protected]